Researchers from the Butantan Institute, a nonprofit manufacturer of immunobiologic solutions for Brazil, recently launched a multi-center, controlled Phase 3 trial that will examine an investigational dengue fever vaccine.
The purpose of the trial is to determine whether the vaccine can adequately protect people from dengue fever, which is carried by mosquitoes.
The vaccine was originally developed at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institute of Health (NIH), under the leadership of Dr. Stephen Whitehead. The NIAID is supporting the Brazil-based trial of the vaccine.
“Researchers in NIAID’s Laboratory of Infectious Diseases spent many years developing and testing dengue vaccine candidates designed to elicit antibodies against all four dengue virus serotypes,” NIAID Director Dr. Anthony Fauci said. “Earlier clinical trials of this candidate conducted in the United States by NIAID showed that it could elicit a robust antibody and cellular immune response after just one dose. Because the impact of dengue fever in Brazil is especially large and the country has an excellent health infrastructure, it is an ideal location to test the vaccine candidate.”
Dengue is typically found in the subtropic and tropic regions of the world. Approximately 50 percent of the global population is considered at risk for developing the illness. Each year, approximately 400 million people contract the virus, and approximately 500,000 of these people receive hospitalization. In Brazil alone, there were over 1.5 million dengue cases in 2015.